RU58841

Short Description:

RU58841 is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of RU58841 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery.

RU58841 (also known as RU-58841) is a compound, RU58841 competes with dihydrotestosterone to keep DHT levels within the normal range, thereby regulating the hair growth cycle. It stimulates the conversion of new hair follicles into anagen hair follicles by entering the anagen phase. Allowing the damaged follicles time to transition back to normal growth phase helps the cells recover. It also increases blood flow to damaged follicles and helps them regenerate. On the other hand, RU58841 (RU-58841) works by binding to androgen receptors in hair follicles. So the androgens don’t have the chance to bind and start the chain reaction of androgenetic alopecia and start the process called miniaturization. It has been shown to locally interrupt this hair loss message so that normal hair growth can continue.

RU58841 Also called Minoxidil was the first drug approved by the FDA for the treatment of androgenetic alopecia (hair loss). Before that, minoxidil had been used as vasodilator drug prescribed as oral tablet to treat high blood pressure, with side effects that included hair growth and reversal of male baldness. In the 1980s, UpJohn Corporation came out with a topical solution of 2% minoxidil, called Rogaine, for the specific treatment of androgenetic alopecia. Since the 1990s, numerous generic forms of minoxidil have become available to treat hair loss while the oral form is still used to treat high blood pressure.

Minoxidil is a vasodilator medication known for its ability to slow or stop hair loss and promote hair regrowth. It is available over the counter for treatment of androgenic alopecia, among other baldness treatments, but measurable changes disappear within months after discontinuation of treatment. Its effectiveness has largely been demonstrated in younger men (18 to 41 years of age), the younger the better, and in those with balding in the central (vertex) portion of the scalp.

FOB Price: US 5 - 2000 / KG

Min.Order Quantity: 1 KG

Supply Ability: 10000 KG/per Month

Port: Shanghai /Beijing

Payment Terms: L/C,D/A,D/P,T/T,O/A

Shipping Terms: By sea/By Air/By Courier

Send email to us Download as PDF

Product Detail

Product Tags

Product Name:RU58841

OtherName:4-[3-(4-Hydroxybutyl)-4,4-dimethyl-2,CAS No:154992-24-2

Specifications: 99.0%

Colour: White powder with characteristic odor and taste

GMO Status:GMO Free

Packing: in 25kgs fiber drums

Storage:Keep container unopened in cool, dry place,Keep away from strong light

Shelf Life:24 months from date of production

RU58841: Topical Anti-Androgen for Hair Loss Research
Non-Steroidal DHT Blocker with Localized Action

Product Overview

RU58841 (CAS: 154992-24-2), also known as PSK-3841 or HMR-3841, is a non-steroidal anti-androgen compound initially developed in the 1990s by French scientists . As a competitive androgen receptor antagonist, it binds to hair follicle receptors, blocking dihydrotestosterone (DHT) from triggering androgenetic alopecia (pattern hair loss) without altering systemic hormone levels .

Key Features:

Mechanism: Competes with DHT at scalp receptors, preventing follicle miniaturization .
Localized Action: Acts topically without reducing serum DHT or testosterone .
Efficacy: Clinical trials in primates showed 103% hair regrowth vs. 88% with finasteride .
Purity: ≥99% white powder, soluble in ethanol/propylene glycol carriers .

Scientific Background

Clinical Trials
- Prostrakan’s Phase II trials (2005) demonstrated RU58841′s equivalence/superiority to finasteride over 6 months .
- In stumptail macaques, 5% RU58841 solution outperformed oral finasteride, with no systemic DHT reduction .
- Human trials were discontinued due to unclear reasons (funding, safety, or patent issues) .
Safety Profile
- Reported Side Effects: Local irritation, erythema, and rare systemic effects (e.g., libido changes) .
- Caution: Not FDA-approved; limited long-term human safety data available .

Usage Guidelines

Preparation:

Mix 30-100mg RU58841 powder with 70% ethanol + 30% propylene glycol (e.g., 0.7ml ethanol + 0.3ml PG per 1ml solution) .

Application:

Cleanse and dry scalp thoroughly.
Apply 1ml solution daily (preferably nighttime) to affected areas .
Avoid concurrent use with oily products to enhance absorption .

Storage:

Store powder at -20°C; prepared solution stable for 30 days at room temperature .

Advantages Over Alternatives

Feature	RU58841	Finasteride/Minoxidil
Action Scope	Localized (scalp-only)	Systemic DHT reduction
Hormonal Impact	No serum DHT/T change	Reduces DHT by 70%
FDA Approval	Research compound	FDA-approved OTC
Gender Suitability	Effective in both men & women	Primarily for men

Purchasing & Compliance

Legal Status: Classified as a research chemical; not for human/animal therapeutic use .
Suppliers: Available through specialized vendors (e.g., Anageninc, Lyphar Biotech) with regional shipping .
Disclaimer: Consult healthcare professionals before use. Compliance with local regulations is mandatory .